Impact of Scedosporium apiospermum complex seroprevalence in patients with cystic fibrosis - Université d'Angers Accéder directement au contenu
Article Dans Une Revue Journal of Cystic Fibrosis Année : 2014

Impact of Scedosporium apiospermum complex seroprevalence in patients with cystic fibrosis

Perrine Parize
  • Fonction : Auteur
Anne-Lise Bienvenu
Stéphanie Bourdy
  • Fonction : Auteur
Marie Le Pogam
  • Fonction : Auteur
Philippe Reix
Stéphane Picot
Olivier Lortholary
  • Fonction : Auteur
Isabelle Durieu
  • Fonction : Auteur

Résumé

Background

Species of the Scedosporium apiospermum complex (S. a complex) are emerging fungi responsible for chronic airway colonization in cystic fibrosis (CF) patients. Recent studies performed on Aspergillus fumigatus suggest that the colonization of the airways by filamentous fungi may contribute to the progressive deterioration of lung function.

Methods

We studied S. a complex seroprevalence, as a marker of close contact between patient and the fungi, in a large monocentric cohort of CF patients attended in a reference centre in Lyon, France.

Results

Serum samples from 373 CF patients were analysed. Antibodies against S. a complex were detected in 35 patients (9.4%). In multivariate analysis, S. a complex seropositivity was only associated with seropositivity to A. fumigatus.

Conclusions

This study does not suggest an association between sensitization against S. a complex and poorer lung function in CF. Prospective studies are needed to evaluate the impact of both seropositivity and S. a complex colonization on the course of CF.

Dates et versions

hal-03333780 , version 1 (03-09-2021)

Identifiants

Citer

Perrine Parize, Sandrine Nail-Billaud, Anne-Lise Bienvenu, Stéphanie Bourdy, Marie Le Pogam, et al.. Impact of Scedosporium apiospermum complex seroprevalence in patients with cystic fibrosis. Journal of Cystic Fibrosis, 2014, 13 (6), pp.667-673. ⟨10.1016/j.jcf.2014.01.011⟩. ⟨hal-03333780⟩

Collections

UNIV-ANGERS
12 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More